ArticleJournal of advanced research2026
MetsObesity: a novel classification system for predicting 15-year cardiovascular risk in the UK Biobank population.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multidomain Biomarkers as Predictors of Cardiovascular Risk in Acute Coronary Syndrome: A Prospective Evaluation.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity phenotyping often fails to capture the heterogeneity in cardiovascular risk. Current approaches rely heavily on BMI or conventional metabolic syndrome criteria, which underestimate cardiometabolic risk in a large proportion of population. We aimed to develop and validate a novel, clinically scalable classification system, MetsObesity, to predict long-term cardiovascular outcomes in people with obesity and/or other metabolic abnormalities. METHODS AND
findingsUsing data from 346,001 participants in the UK Biobank (median follow-up: 15 years), we applied random forests and recursive feature elimination algorithms to identify key predictors of cardiovascular events across metabolic, anthropometric, and additional abnormalities domains. The SHapley Additive exPlanations (SHAP) model was employed to explore the interpretability of variables selection. These variables informed a five-tier classification system (MetsObesity Classes 1-5). Cox proportional hazard models were used to assess associations with major adverse cardiovascular events (MACE). Model performance was evaluated using discrimination (C-index), calibration, and decision curve analysis. In the validation cohort (n = 173,000), the incidence of MACE was 1.4%, 3.3%, 5.0%, 6.0%, and 8.5% across the five classes, respectively. MetsObesity significantly outperformed BMI, waist circumference, body fat percentage, and existing metabolic syndrome definitions in predicting incident MACE. Participants in Classes 4 and 5 had 2-4-fold higher hazard ratio than traditional obesity classifications. The model demonstrated robust calibration and clinical net benefit across subgroups. Lack of external validation is the key limitation of this study.
conclusionsThe MetsObesity offers a novel, interpretable, and implementable framework for cardiovascular risk stratification in people with obesity and metabolic abnormalities. Integration of routinely available clinical variables allows scalable application across healthcare settings. This classification has potential to inform risk-based prevention strategies and redefine cardiometabolic screening in global health systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.